Famous Amos Ingredients for Success Entrepreneurs Initiative

NOFA-VT’s Farmer Emergency Fund, established in 1997, supports organic and NOFA-VT member farmers who have been adversely affected by natural and unnatural disasters. The NOFA-VT Farmer Emergency Fund is available to assist farmers who are in financial need after having been adversely affected by natural and unnatural disasters. -$2,500 grants are available for commercial farmers who are NOFA-VT members. Applying farmers will need to be NOFA-VT members in good standing for at least one year before being eligible to apply for funds. -$5,000 grants are available to any farm that is VOF certified organic. Because we want to incentivize organic certification, and because of the commitment involved in getting certified, we will waive the one-year waiting period for certified organic farms.

A structured component of Mesa Business Builder offering one-on-one consulting, training, and professional advising (digital and in-person support). Supports micro- and underserved businesses through measurable milestones. This program offers free services and grant packages to small businesses in Mesa, AZ. The lifetime cap of these services is $20,000 per business

The Proof of Concept program provides up to $25,000 to conduct research that demonstrates the technical and economic feasibility of an innovation before it is commercialized. The program is open to those committed to commercializing an innovation in South Dakota, such as entrepreneurs, universities, existing South Dakota companies and other entities. Investment proceeds may be used to pay consultant contracts, material and supplies, salaries for employees in South Dakota, and necessary services for technical feasibility or marketing studies.

The City of Hercules has allocated $200,000 to attract certain types of desired eating and drinking businesses, and general businesses in larger retail spaces, by helping with move-in costs. The program provides grants of $5,000 (minimum) to $25,000 (maximum) for qualified new eating & drinking establishments, and $50,000 to $100,000 for qualified general businesses in larger spaces. The grant amount must be matched by the applicant.

This Notice of Funding Opportunity (NOFO) encourages applications for investigator-initiated, early phase, clinical trials of natural products (i.e., botanicals, dietary supplements, and probiotics), which have a strong scientific premise to justify further clinical testing. For this NOFO, natural products include promising nutritional regimens that standardize the amount of a specific naturally occurring nutritional compound (e.g., omega-3 fatty acids, anthocyanidins, or polyphenols) and have compelling preliminary evidence. Under this NOFO, trials must be designed so that results, whether positive or negative, will provide information of high scientific utility and will support decisions about further development or testing of the natural product. This NOFO will provide up to 3 years support for studies to replicate the impact of the natural product on target engagement when used by humans, and assess whether there is an association between the degree of the impact on target engagement and functional or clinical outcomes in a patient population. Applications are encouraged to design studies to determine how to optimize the impact of the natural product on target engagement by optimizing the delivery of the natural product through examination of different doses or formulations. In addition, applications can be designed to combine the natural product with another treatment approach that is known to engage the same target; or study the impact of the natural product in a target population that is more responsive. Clinical trials submitted under this NOFO are expected to be hypothesis based, milestone-driven, and directly related to the research priorities and mission of NCCIH. This R33 funding mechanism is intended to accelerate the translation of emerging basic science findings about natural products into early-stage clinical testing to determine whether continued clinical research is warranted. This NOFO will not support efficacy or effectiveness trials, nor will